INTRODUCTION
P rimary congenital glaucoma (PCG), alternatively known as developmental glaucoma, is a developmental eye defect, primarily caused by the abnormal development of anterior chamber angle during neonatal or infantile stage [1] .
Typically, most patients display glaucomatous phenotypes during birth, but in some cases its onset has also been observed at adolescence [2] . Typical symptoms of PCG include tearing, photophobia, and blepharospasm [3] . In absence of any treatment, ocular hypertension can lead to irreversible damage to the optic nerve, thereby resulting in reduced vision or subsequent complete blindness. Congenital glaucoma has been shown to be a hereditary disease transmitted in an autosomal recessive pattern [4] . Although it's complete etiology has not been thoroughly elucidated, genetic cause is believed to be the most important risk factor in PCG patients. Since the first genetic study in PCG patients [5] , multiple genetic loci in the gene GLC3 have been identified, including GLC3A [5] , GLC3B [6] , GLC3C, and GLC3D [7] . These studies have shown the presence of two pathogenic genes, cytochrome P450 1B1 (CYP1B1) and latent-transforming growth factor beta-binding protein 2 (LTBP2) on these genetic loci. The mutation in the CYP1B1 gene is considered as the most common pathological reason for congenital glaucoma. Typically, CYP1B1 protein structure display 4 conserved helix bundles, including J-helix, K-helix, β-sheets, meander region, and heme-binding region [8] . In addition, the N-terminus hinge region and C-terminus conserved core structures (CCSs) have been reported to be the most crucial regions for maintaining the fundamental properties of CYP1B1 [2, 9] . Interestingly, the clinical reports from different ethnic groups showed that PCG patients, with CYP1B1 mutations, like missense mutations of W57C [9] and G365W [10] in the N-terminus hinge region or CCSs, generally have more severe glaucomatous phenotypes.
To date, more than 150 mutation variants of CYP1B1 gene have been found in congenital glaucoma patients worldwide [11] . In Chinese patients, 43 mutation variants have been reported, including R390H, the common mutation identified in PCG patients from all ethnic groups, and L107V mutations uniquely identified in Chinese PCG patients only [12] . Based on this information, we in our study have tried to investigate if any novel CYP1B1 gene mutations exist in PCG patients from Shandong province of China. To address it, we analyzed the CYP1B1 gene individually from 13 PCG diagnosed Chinese patients, and 50 healthy controls from Shandong Province by direct sequencing of its coding region. The structure of the mutated protein was analyzed through PyMOL software (USA). The severe glaucomatous phenotype of one PCG patient with novel mutation indicated the important role played by specific mutational allele in regulating CYP1B1 gene function during development.
SUBJECTS AND METHODS Ethical Approval
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University. The informed consents were obtained from each subject or his/her guardian for their participation in this study. The ocular examination of the sporadic PCG patients and ethnically matched healthy controls were performed at Affiliated Hospital of Qingdao University. The examination included vision tests, intraocular pressure (IOP), slit lamp biomicroscopy, corneal diameter, and cup-to-disc ratio. Based on these clinical reports, patients with other ocular diseases beside PCG or systemic illnesses were excluded from this study. Based on the IOP, 13 sporadic PCG patients with IOP of higher than 21 mm Hg, and 50 healthy controls with IOP lower than 21 mm Hg, were eventually selected for this study. Peripheral blood samples were collected from all subjects. Leukocyte DNA were extracted using Massive Whole Blood Genomic DNA Extraction Kit (BioTeke, Beijing, China). The coding region of CYP1B1 gene was amplified from the genomic DNA by polymerase chain reaction (PCR). The PCR reaction was performed in a 25 µL reaction mixture containing 0.1 µg genomic DNA, 40 µmol/L forward and reverse primers (Table 1) , 3 mmol/L magnesium chloride and 2×Hieff TM PCR Master Mix (YESEN Biotech Co., Shanghai, China). The following PCR conditions were used for amplification: an initial denaturation step at 95℃ for 5min, 32 cycles of denaturation at 95℃ for 30s, annealing temperature for 30s, and extension at 72℃ for 30s, with final additional extension time of 10min at 72℃. The amplified PCR products were subjected to agarose gel electrophoresis and the target PCR fragments were extracted from Biowest Agarose by QIAquick Gel Extraction Kit (QIAGEN, Shanghai, China). Next, the direct sequencing of the amplified product was completed using amplification primers (Ruibo Xingke Biotech Co. Beijing, China), and the sequences were analyzed using Chromas V2.3, DNAman V7.0 software along with PubMed Blast (https://blast.ncbi.nlm.nih. gov/Blast.cgi) search engine. In addition, the sequence of wild-type CYP1B1 gene was downloaded from https://www.rcsb.org, and saved as PDB file. The mutated amino acids in the CYP1B1 protein were changed manually using ICMpro software, and the PDB files were uploaded into PyMOL software to generate 3D structure of the protein. The mutated amino acids and key ligands were labeled in different colors. RESULTS Among the total 13 primary congenital glaucoma patients included in our study, 12 were males and 1 female, with age ranging from 3 to 23y. The median age at the time of diagnosis was 3mo. In addition, one patient had unilateral ocular abnormality diagnosis, while all other 12 patients were diagnosed with bilateral congenital glaucoma. The average IOP prior to surgeries in these patients was 37.19 mm Hg and the mean corneal diameter was 13 mm. The analysis of CYP1B1 gene led to the identification of two missense mutations in one of the 13 PCG patients through direct sequence analysis, including c.988G>T [G=0.00000 (0/112670, ExAC)] and c.989C>T [A=0.00000 (1/244488, GnomAD)] (P.A330F) and c.1169G>A [T=0.00009 (22/244260, GnomAD)] (P.R390H) (Figure 1 ). These variants were not detected in any of the 50 healthy controls. In comparison to the previous studies, R390H mutation was common in Chinese PCG patients [13] , but A330F mutation was novel in Chinese Han population. It is also important to highlight that it is for the first time that these two mutations were identified in single PCG patient worldwide. Furthermore, in addition to these two missense mutations, four other single-nucleotide polymorphisms (SNPs) were also identified in other analyzed PCG patients or healthy controls, including c.142C>G (P.R48W), c.355G>T (P.A119S), c.1347T>C (P.D449D), and c.1294C>G (P.L432V). Next, to predict the functional correlation of these mutations in the CYP1B1 gene, protein structure was analyzed using PyMOL software. As shown in Figure 2 , A330F and R390H mutations disrupted the orientation of I-helix and K-helix, respectively. More specifically, the link between the substrate binding region and the CCS, the torsion of I-helix switched lactamine into phenylalanine in the side chain of the protein. The benzene ring in the phenylalanine can form the connections with the α-naphthoflavone (ANF) ligand, and thus can create stearic hindrance between ANF ligand and heme iron. In addition, another mutation R390H changed K-helix in CCS, and resulted in the formation of unstable heme-protein complex. Together, these findings indicated that both A330F and R390H were important alleles to maintain the fundamental properties of CYP1B1 gene, and might contribute to severe clinical phenotype. Interestingly, our clinical findings confirmed our assumption that PCG patient with A330F and R390H mutations exhibited severe glaucoma phenotype. This patient specifically had PCG symptoms at birth with photophobia, tearing, and corneal whitening. However, no family history of PCG has been identified in this patient. As shown in Figure 3 , the IOPs in the right and left eye of this patient were 42 and 43 mm Hg, respectively, at 6-month of age, and both horizontal corneal diameters were 12 mm. Goniotomy was performed on both eyes of this patients at Linyi People's Hospital, and after the surgery, the reduced IOPs were maintained for 6mo, but then gradually increased. At the age of 3 years, the IOP of both eyes reached up to 50-60 mm Hg. Subsequently, after trabeculotomy, the postoperative IOPs were again reduced, and maintained for only another 6mo. After the patient turned 11-years-old, the corrected visions were only 0.07 and 0.05 and the IOPs of his right and left eye reached to 39 and 36 mm Hg, respectively. Goniotomy along with trabeculotomy was again performed to reduce his IOPs. Surprisingly, the elevated IOPs could not be reduced effectively this time. Later glaucoma valve was implanted to his left eye in the affiliated hospital of Qingdao University, which then led to reduced IOPs of 16 mm Hg. Next, with the help of betamethanil eye drops, the IOPs were stabilized at 18-23 mm Hg for the right eye, and 14-16 mm Hg for the left eye. More recently, the corrected vision of the right eye was 0.05, and for the left eye, it was finger counting (10 cm), with corneal diameter of 13 mm, for both eyes. The structures behind the iris could not be observed by slit lamp, due to the adherence of iris in the pupil area to mildly opaque lens.
DISCUSSION
The congenital glaucoma has mainly been characterized as genetically inherited disease, and specifically CYP1B1 gene mutations show association with its pathogenesis [14] [15] [16] [17] .
Importantly, more than 150 mutations in the CYP1B1 gene have been reported to be associated with PCG pathophysiology, but recently specific CYP1B1 mutations have been predominantly linked with severe glaucomatous phenotypes [18] . Our study detected common variant, R390H in the CYP1B1 gene among Chinese PCG patient. This mutation has been reported in different ethnic groups worldwide [19] [20] , and has been shown to cause severe angle abnormalities. In addition, our study also demonstrated the presence of another novel variant, A330F among the same Chinese PCG patient. However, this additional variant has previously been only reported in Japanese [21] and South Korean [22] . According to the SNP database in NCBI (https://www.ncbi.nlm.nih.gov/SNP/snp_ ref.cgi?locusId=1545), the mutant allele frequency of A330F is much lower than the frequency in R390H. The presence of A330F in limited number of PCG patients in Asia suggest that it is a different allele, capable of inducing severe PCG phenotypes. Up until this report, no evidence existed about the co-occurrence of both these two missense mutations, R390H and A330F, in same congenital glaucoma patient. The Chinese PCG patient in our study was indeed the first one to show this trend in the world. Further clinical observation confirmed the correlation between the presence of these mutations and patient displaying severe glaucomatous phenotypes. Multiple surgeries and combined medicinal treatment was required to reduce the elevated IOP in this patient.
As the functional importance of CYP1B1 can be predicted through its protein structure analysis [23] , it can act as an excellent strategy to understand the correlation between specific mutations and severe angle abnormalities. The carboxyl terminus of CYP1B1 protein includes a substrate binding region and CCS, while the N-terminal of CYP1B1 protein includes a membrane-spanning domain and a hinge region. Generally, the critical mutations in CYP1B1 gene has been located in the hinge region and CCS [2] . The critical mutation, R390H observed in our study usually disrupt the orientation of K-helix in CCS, which then affects the formation of a stable haemoglobin complex and molecular folding [9, 24] . This mutation clearly changes the fundamental features of CYP1B1, and can lead to severe developmental abnormalities as reported previously [22] . Another mutation detected in the CYP1B1 gene in PCG patient in our study was A330F, which is located in the I-helix and provide link between substrate binding region and CCS. Historically, the mutation in this region is not as common as R390H, and thus has not been previously considered very crucial in PCG patients. However, recently more and more numbers of PCG patients have confirmed the close correlations between severe phenotypes and this mutation. In addition, mutations like E229K [25] and S239R [26] , have also been shown to involved in the disruption of the three-dimensional structures of I-helix, and subsequently lead to severe glaucomatous phenotypes. Moreover, consistent with earlier analysis, our structural analysis also suggested that the mutation in the I-helix can block binding of substrates with heme iron. Altogether, these cumulative evidences indicate that the link region is also an equally important domain for maintaining the function of CYP1B1 gene, besides the hinge region and CCS. The CYP1B1 enzyme has been shown to play an important and crucial catalytic role in the cholesterol, steroids, and other lipids synthesis [27] [28] [29] . All these metabolic reactions and products seem to be important in the differentiation and growth of multiple tissues. In the context of PCG, CYP1B1 mutations cause significant change in retinol, which is the key metabolite for the development of trabecular meshwork (TM) [30] [31] . Multiple studies have indicated about the important roles of retinol in the TM development; like mutations in the retinol receptor gene and the retinoic acid receptor β cause severe developmental defects [32] . The retinoic acid receptors and retinoid X receptors expressed in the TM can transform retinol into its active derivatives which then regulate the transcription of myocilin gene [29, 33] . In addition, the function of the CYP1B1 gene in regulating aqueous humor outflow is controversial, but glaucoma pathology is highly related with the mutation and expression of this gene. In our study, we speculate that heme instability caused by R390H and A330F mutations can lead to the abnormalities in retinol metabolism, and is supported by the functional studies published in recent years [30] . Collectively, the evidence indicates that the retinol metabolic abnormalities due to R390H and A330F mutation might contribute to severe glaucomatous phenotypes in PCG patients. Alternatively, Vol. 12, No. 6, Jun.18, 2019 www.ijo.cn Tel: 8629-82245172 8629-82210956 Email: ijopress@163.com another major cause of TM pathogenesis can be abnormal oxidation status due to abnormal CYP1B1 gene activity. Presence of oxidative stress during early development can cause TM hypoplasia, which then can lead to PCG development [34] . It has been specifically reported that antioxidant enzymes are deficient in the TM of PCG patient, and the presence of high H 2 O 2 and superoxide anions in the aqueous humour can easily facilitate their infiltration into the TM, and can subsequently exert oxidative stress, eventually leading to TM pathogenesis [35] . Currently, goniotomy is the major approach to treat congenital glaucoma. Although the single surgery can benefit certain PCG patients, but in some patients with specific mutations in CYP1B1 genes, repetitive surgeries combined with other medicine are required for treatment. But the combined treatments are also not effective to reduce IOP in these patients, and therefore, it is necessary to explore novel approaches for treatment of PCG patients, especially for the patients like in our study with multiple CYP1B1 mutations. In this direction, a recent study reported that abnormal cellular function of TM cells from CYP1B1 -/-mouse can be restored by the treatment with the free radical scavenger, N-acetylcysteine [34] . Similarly, supplementing antioxidant enzymes or/and the retinol to the TM, can also probably benefit PCG patients with A330F and R390H mutations. In addition, the CRISPR-Cas9 based gene therapy and stem cells-based therapy have also been reported as promising approaches to rescue the glaucomatous phenotypes for open-angle glaucoma through rebuilding damaged TM [36] [37] . Thus, it would be interesting to test these approaches in PCG patients. Overall, our study demonstrated the presence of novel mutations in the Chinese PCG patients. This is the first report about co-existence of A330F and R390H mutations in the same PCG patient. Furthermore, the structural changes caused by these two mutations renewed our current understanding about the role of key domains of CYP1B1 gene in influencing congenital glaucoma phenotype. It is evident that besides CCS domain, additional regions can also affect the structure of CCS, and are crucial in regulating the function of CYP1B1 in terms of causing TM abnormalities. However, future studies are required to determine the major influence of these mutations on metabolism and selection of key metabolites, which can probably lead to the development of potential strategies for PCG therapy.
